GSK plc (SA:G1SK34) — Market Cap & Net Worth
Market Cap & Net Worth: GSK plc (G1SK34)
GSK plc (SA:G1SK34) has a market capitalization of $114.11 Billion (R$581.52 Billion) as of April 18, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #182 globally and #8 in its home market, demonstrating a 0.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GSK plc's stock price R$57.96 by its total outstanding shares 10033210790 (10.03 Billion).
GSK plc Market Cap History: 2020 to 2026
GSK plc's market capitalization history from 2020 to 2026. Data shows growth from $73.39 Billion to $114.11 Billion (7.64% CAGR).
GSK plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GSK plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.27x
GSK plc's market cap is 3.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
18.68x
GSK plc's market cap is 18.68 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $73.39 Billion | $34.10 Billion | $5.75 Billion | 2.15x | 12.77x |
| 2021 | $103.44 Billion | $34.11 Billion | $4.38 Billion | 3.03x | 23.59x |
| 2022 | $67.95 Billion | $29.32 Billion | $14.96 Billion | 2.32x | 4.54x |
| 2023 | $69.17 Billion | $30.33 Billion | $4.93 Billion | 2.28x | 14.04x |
| 2024 | $81.82 Billion | $31.38 Billion | $2.58 Billion | 2.61x | 31.77x |
| 2025 | $106.80 Billion | $32.67 Billion | $5.72 Billion | 3.27x | 18.68x |
Competitor Companies of G1SK34 by Market Capitalization
Companies near GSK plc in the global market cap rankings as of April 18, 2026.
Key companies related to GSK plc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $829.71 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #19 globally with a market cap of $564.21 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #33 globally with a market cap of $368.45 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $317.50 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $829.71 Billion | $927.03 |
| #19 | Johnson & Johnson | NYSE:JNJ | $564.21 Billion | $234.18 |
| #33 | AbbVie Inc | NYSE:ABBV | $368.45 Billion | $208.38 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $317.50 Billion | $204.80 |
GSK plc Historical Marketcap From 2020 to 2026
Between 2020 and today, GSK plc's market cap moved from $73.39 Billion to $ 114.11 Billion, with a yearly change of 7.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$114.11 Billion | +6.84% |
| 2025 | R$106.80 Billion | +30.53% |
| 2024 | R$81.82 Billion | +18.28% |
| 2023 | R$69.17 Billion | +1.80% |
| 2022 | R$67.95 Billion | -34.31% |
| 2021 | R$103.44 Billion | +40.95% |
| 2020 | R$73.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of GSK plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $114.11 Billion USD |
| MoneyControl | $114.11 Billion USD |
| MarketWatch | $114.11 Billion USD |
| marketcap.company | $114.11 Billion USD |
| Reuters | $114.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more